slides · global inventory
Table
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 60,557
Current window 44,071-44,100
Pages 2,019
Rows per page 30
Component
44,071-44,100 of 60,557
11
Data presented at EASL 2022, AASLD 2022, GHS 2023.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
15
Data presented at EASL 2023. Includes both a summary table of mean changes and individual patient trajectory charts.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
17
Data presented at AASLD 2023; includes both a summary table and a longitudinal line chart with error bars.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
19
The slide details a specific licensing deal with Qilu Pharmaceutical, including financial terms and geographic scope.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
25
The slide includes a financial disclaimer regarding cash balance and burn.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
14
Uses a pyramid-like growth visualization to represent expanding market opportunities.argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Rising SuccessLoop · Why Now1 hit
15
The slide uses a matrix structure to compare clinical and commercial viability for three indications.argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · The BreakthroughLoop · Quick Win Big Bet1 hit
24
argenx SE | Investor Conference Presentation Deck | 27 slidesargenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
05
The right-hand side is a complex matrix mapping clinical trials to patient segments (HER2-positive, HR-positive, TNBC, gBRCAm) and treatment stages (Neoadjuvant, Adjuvant, Metastatic).AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · Early StrugglesLoop · Logic Chain1 hit
11
The slide uses a three-column layout to categorize business units and their respective growth drivers.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · Rising Success1 hit
14
Includes a table comparing hospitalization rates for RSV, hMPV, and Influenza across age groups.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · Rising Success1 hit
17
The slide uses a split layout: left side details specific drug assets (anselamimab, ALXN2220) with clinical stage data, right side outlines the genomic medicine strategy.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · The BreakthroughLoop · Cost Of Inaction1 hit
19
The slide highlights both internal R&D focus areas and external acquisitions (Cellectis, Quell, Gracell) to support long-term growth.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
05
The slide uses a table-like structure to track progress (checkmarks for completed, squares for upcoming) across 8 distinct drug programs.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
11
Includes a map of global disease burden and key product features.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
21
Includes a map of the world as a visual anchor for global disease burden.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
24
The slide uses a feature-comparison matrix to highlight the unique value proposition of DMX-1002.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
26
ATAI | Investor Presentation Deck | 34 slidesATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
31
Includes a map of global disease burden and key product features.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
07
BenevolentAI | Investor Conference Presentation Deck | 22 slidesBenevolentAI | Investor Conference Presentation Deck | 22 slides · BenevolentAI
Conference presentation Investor relations Beat · Market SizeLoop · Cost Of Inaction1 hit
17
The slide uses a Gantt-style visualization to show the status of various drug development programs.BenevolentAI | Investor Conference Presentation Deck | 22 slides · BenevolentAI
Conference presentation Investor relations Loop · Golden Circle1 hit
20
The table presents normalized operating loss and EPS, excluding specific exceptional items as detailed in the footnotes.BenevolentAI | Investor Conference Presentation Deck | 22 slides · BenevolentAI
Conference presentation Investor relations Beat · Financials1 hit
21
The table reconciles reported operating loss to normalised operating loss by adding back non-recurring restructuring and transaction-related costs.BenevolentAI | Investor Conference Presentation Deck | 22 slides · BenevolentAI
Conference presentation Investor relations Beat · Financials1 hit
22
The slide provides a bridge between operating loss and cash flow, with explanatory notes on the right.BenevolentAI | Investor Conference Presentation Deck | 22 slides · BenevolentAI
Conference presentation Investor relations Beat · Financials1 hit
08
The chart uses a Gantt-style visualization to show the progress of drug candidates through clinical phases.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
13
Data cut date: 15Nov23BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
14
Data cut date: 15Nov23. Pt = Platinum.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
15
Data table showing safety profile by dose cohort.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
16
The slide highlights a low incidence of immune-related adverse events (2 out of 18 patients).BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
18
The chart is a spider plot (or swimmer plot variant) showing change in target lesion size over time for individual patients.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit